ZTS stock sentiment todayZoetis Inc
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
ZTS
Zoetis IncA dominant market leader in animal health with high-margin recurring revenue and superior pricing power compared to human pharma.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ZTS. Not financial advice.
Price · last 12 months
Gossip
The narrative centers on the 'humanization of pets' trend, where owners prioritize pet healthcare even during downturns. Recent chatter focuses on the blockbuster potential of Librela and Solensia (monoclonal antibodies for pain) and a recovery in livestock margins following supply chain stabilization.
- ·Launch of next-gen parasiticides
- ·Expansion into monoclonal antibody pain treatments
- ·Resilience of pet spending vs. discretionary retail
- ·Direct-to-consumer marketing success for pet meds
Financial
Zoetis maintains industry-leading EBITDA margins (approx. 40%) and a robust balance sheet. Unlike human pharma, it faces no 'patent cliff' risk, as animal health products have longer lifecycles and lower generic competition.
- ·Consistent double-digit organic revenue growth
- ·ROE consistently above 45%
- ·Low capital intensity with high free cash flow conversion
- ·Strong pricing power offsetting inflationary costs
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·Insiders bought a net $886K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High valuation premium (P/E) relative to the broader healthcare sector
- ·Potential regulatory scrutiny over long-term effects of new biologic drugs
- ·Impact of economic slowdown on premium livestock feed and elective veterinary visits
Peer temperature
How direct competitors stack up against ZTS right now.
- HOTIDXXIDEXX Laboratories
HOTTER — trading at a higher multiple but driven by even stickier, high-margin recurring diagnostic software and equipment revenue.
See full analysis → - COLDELANElanco Animal Health
COLDER — struggling with higher debt leverage and slower innovation pipelines compared to Zoetis's R&D output.
See full analysis → - NEUTRALMRKMerck & Co. (Animal Health Unit)
NEUTRAL — offers stability but pet health growth is often overshadowed by human oncology (Keytruda) headwinds and patent expirations.
See full analysis →
- ZTS+1.9%
- IDXX-8.4%
- ELAN-6.6%
- MRK+17.1%
Analyst price target
Consensus average of 10 analysts · median 94.00
Source: StockAnalysis.com · updated 2026-08-24
AI-generated analysis for informational purposes only. Not financial advice.